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Flavin-containing monooxygenases (FMOs) are ubiquitous in all domains of life and metabolize a 18 
myriad of xenobiotics including toxins, pesticides and drugs. However, despite their 19 
pharmacological significance, structural information remains bereft. To further our understanding 20 
behind their biochemistry and diversity, we scrutinized three ancient mammalian FMOs: 21 
AncFMO2, AncFMO3-6 and AncFMO5, using Ancestral Sequence Reconstruction, kinetic and 22 
crystallographic techniques. Remarkably, all AncFMOs could be crystallized, and were structurally 23 
resolved between 2.7 and 3.2 Å. These crystal structures depict the unprecedented topology of 24 
mammalian FMOs. Each employs extensive membrane-binding features and intricate substrate-25 
profiling tunnel networks through a conspicuous membrane-adhering insertion. Furthermore, a 26 
glutamate–histidine switch is speculated to induce the distinctive Baeyer-Villiger oxidation activity 27 
of FMO5. The AncFMOs exhibited catalysis akin to human FMOs and, with sequence identities 28 
between 82 and 92%, represent excellent models. Our study demonstrates the power of ancestral 29 
sequence reconstruction as a strategy for the crystallization of proteins.   30 
      31 
Introduction 32 
Xenobiotic metabolism is an ancient and imperative process pursued by all organisms. With 33 
evolution resulting in the production of, and thus exposure to, a vast number of noxious and toxic 34 
natural products,1 organisms have employed a multitude of intricate detoxification systems, to 35 
tackle the sheer quantity of diverse chemicals.1–6 Flavin-containing monooxygenases (FMOs; EC 36 
1.14.13.8) represent one of these detoxifying protein families and are prevalent in all domains of 37 
life.4,7 FMOs are members of the Class B flavin-dependent monooxygenases and utilize the 38 
cofactors FAD and NADP(H), and dioxygen for activity.8–10 Typically, FMOs pursue catalysis as 39 
illustrated in Scheme 1, whereby a soft nucleophile (here demonstrated with trimethylamine) 40 
receives the distal oxygen atom from the C4a-(hydro)peroxyflavin intermediate.11,12 The more 41 
water-soluble hydroxylated product is then released by the enzyme to be excreted from the host. 42 
Humans possess five FMO isoforms that are differentially expressed in many different tissues such 43 
as the kidney, lung, and liver.2,10,13,14 The human FMO genes are found on chromosome 1, with 44 
FMO1-4 clustering over 220 kb, and FMO5 found on a separate chromosome region.15,16 The 45 
human FMO family contains six non-expressed pseudogenes which are also located on 46 
chromosome 1.16 FMOs are involved in phase I of xenobiotic detoxification.2,3 They oxidize an 47 
array of compounds bearing soft nucleophilic centers such as nitrogen and sulfur atoms,2,17–19 48 
making them clinically important regarding drug metabolism.3,6,12,15,17,20,21 The most extensively 49 
characterized FMO is human FMO3, renowned for its production of trimethylamine N-oxide.22–26 50 
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FMO3 deactivation upon mutation induces trimethylaminuria (“fish odor syndrome”), whereby the 51 
body has an unpleasant smell due to the accumulation of trimethylamine.27–30 Whilst FMO4 has not 52 
been extensively characterized, FMO1 and FMO3 were shown to have broad substrate ranges, 53 
metabolizing substrates as diverse as itopride (acetylcholine esterase inhibitor), and tamoxifen (anti 54 
breast-cancer drug).2,31–34 Also FMO2 features a rather broad substrate profile, acting on pesticides 55 
such as napthylthiourea,19 although its role in human metabolism remains partly unknown because 56 
FMO2 is not expressed in the majority of humans due to a mutation.35,36 FMO5 is distinct from the 57 
other FMOs because it is able to perform Baeyer-Villiger oxidations (Scheme 1),37 metabolizing 58 
ketone-containing drugs such as pentoxifylline (a muscle-pain killer).17 Recent literature documents 59 
that FMOs are associated to diseases such as atherosclerosis and diabetes,23,26 promote longevity,38 60 
and regulate cholesterol and glucose levels.26,39–41 Despite their discovery over 30 years ago, the 61 
determinants underlying the existence of five isoforms remain unexplored and even more strikingly, 62 
no mammalian FMO has been structurally elucidated. This gap in our knowledge on these key 63 
enzymes of human drug metabolism likely reflects their distinctive feature: unlike bacterial, fungal, 64 
and insect FMOs that are soluble, mammalian FMOs are insoluble and reside in the membranes of 65 
the endoplasmic reticulum.2,5 66 
 67 
Scheme 1. The catalytic mechanism of FMOs. FADox is reduced by NADPH. FADred is 68 
consequently oxidized by a molecule of dioxygen to generate the C4alpha-(hydro)peroxide 69 
intermediate. The typical mode of action of FMOs with the distal oxygen atom from the 70 
intermediate being inserted onto a soft nucleophile through nucleophilic addition is shown with 71 
reference to trimethylamine. The Baeyer-Villiger monooxygenation activity conducted by human 72 
FMO5 is shown on the right with reference to heptan-2-one. The dotted arrow indicates the 73 
uncoupling reaction whereby the C4alpha-(hydro)peroxide intermediate decays with the release of 74 


































To gain insight into the historical events leading to the paralogs divergence in mammals, we 77 
generated three ancestral FMOs (i.e. the last common ancestors of extant mammalian FMO2s, 78 
FMO3s/FMO6s and FMO5s; herein referred to as AncFMOs) using Ancestral Sequence 79 
Reconstruction:42,43 These enzymes were successfully expressed in E. coli and purified as holo 80 
(FAD-containing) and active enzymes. Despite countless failed crystallization attempts of human 81 
FMO3 and human FMO5, we were able to crystallize and structurally elucidate each AncFMO. In 82 
this article, we describe the unprecedented membrane-binding features associated with the 83 
mammalian FMO and we illustrate that substrate specificity is controlled by tunnel design rather 84 
than catalytic-site architecture. Furthermore, we demonstrate that the biochemistry of FMOs has 85 




Ancestral sequence reconstruction of mammalian flavin-containing monooxygenases 90 
We inferred the evolutionary history of FMOs from a full phylogeny constructed by including 91 
experimentally-characterized enzymes from Bacteria and Eukarya, plus sequences found by 92 
extensive sequence homology searching and HMM profiling (Supplementary Figure 1 and Data 1). 93 
Our work confirmed the findings of the previous studies by Hernandez et al.16 and Hao et al.44: (i) 94 
jawed vertebrate FMOs are monophyletic and derived from a single common ancestor (Figure 1A, 95 
Supplementary Figure 2); (ii) several duplication events occurred in the terrestrial vertebrates; (iii) 96 
the ancestor of mammals already encoded the five FMO paralogs resulting from four major gene-97 
duplication events (Figure 1A, Supplementary Figure S2 and Data 1); (iv) a sixth mammalian 98 
paralog (FMO6) resulted from a late gene duplication event. FMO6 has been described as a 99 
pseudogene in humans45 but it might be functional in mouse16 and its nature is unknown in other 100 
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Figure 1. Ancestral Sequence Reconstruction of FMOs. A: Condensed Maximum Likelihood 117 
phylogeny of FMOs from jawed vertebrates. Clades are colored according to tetrapod classes: 118 
mammalia (magenta), aves (light orange), amphibia (green) and testudines (teal). Clades on the base 119 
are from other non-terrestrial gnathostomes (black). Rooting was performed according to the 120 
species tree. Above the branches transfer bootstrap expectation values are shown. The emergence of 121 
terrestrial vertebrates (tetrapods, 352 mya)46 is marked with an arrow and cartoons on the left. The 122 
three ancestral nodes that were experimentally characterized are labeled with yellow squares. Fully 123 
annotated phylogeny is presented in Supplementary Figure 2. B: Statistical confidence of ancestral 124 
amino acid states. The highest posterior probability (PP) for each of the inferred ancestral states 125 
(sites) in AncFMOs is shown. Average accuracy for AncFMO2= 0.994, AncFMO3-6: 0.982 and 126 
AncFMO5: 0.987. 127 
 128 
 129 
By performing ancestral sequence reconstruction, we obtained the protein sequences of AncFMOs 130 
from mammals with high posterior probabilities (ranging from 0.98-0.99) (Figure 1B, 131 
Supplementary Data 2). In the phylogeny, we observed that FMO5 diverged earlier in agreement 132 
with previous reports,44 followed by FMO2, FMO1, FMO4 and the FMO3-6 hybrid. This topology 133 
suggests that the gene duplication events took place simultaneously rendering no clear paralog 134 
couples as it has been previously proposed (Figure 1A, Supplementary Figure 2).16,44 Among the 135 
whole clade of present-day FMO2s, 80% of sites are conserved, while the rest are likely responsible 136 
for functional differences among species. We observe that from AncFMO2 to human FMO2, 42 137 
substitutions have occurred of which 18 are conservative (as defined by Grantham47). In the case of 138 
AncFMO3-6, the ancestor underwent an early duplication event originating the FMO3 and FMO6 139 
paralogs in mammals. As a general trend, comparing the pre-duplication ancestor to modern FMO3 140 
and FMO6, 70% of the sites are conserved. Along each branch to the human FMO3 or human 141 
FMO6 sequences, 94-98 substitutions occurred, 28-30 of them being conservative. The lower 142 
degree of conservation is not surprising considering the duplication scenario. Finally, FMO5 is the 143 
most enigmatic of all extant FMOs due to its Baeyer-Villiger oxidation activity.37 AncFMO5 shows 144 






























historical scenario, we selected AncFMO2, AncFMO3-6 and AncFMO5 for experimental 146 
characterization. 147 
 148 
AncFMOs portray catalytic rates similar to those of extant mammalian FMOs  149 
Critically for our project, the hitherto generated AncFMOs sequences proved to encode stable 150 
proteins that can be effectively produced and purified as recombinant, FAD-loaded, and 151 
catalytically competent enzymes in E. coli. Thus, the first relevant result was that a convenient 152 
bacterial expression system for the study and biocatalytic exploitation of close homologs to human 153 
FMOs was established (see materials and methods). We next verified whether these enzymes 154 
retained enzymatic activities by performing steady-state kinetics experiments using a NADPH-155 
depletion spectrophotometric assay. The NADPH oxidase activity was initially tested (NADPH 156 
consumption in absence of an organic substrate; NADPHuncoupling in Table 1). This was followed by 157 
the measurements of the kinetics of the reaction in the presence of known oxygen-accepting 158 
substrates of FMO2 and FMO3 (methimazole, trimethylamine and thioanisole), and FMO5 (heptan-159 
2-one). The results were reassuring in that AncFMO2, AncFMO3-6, and AncFMO5 proved to be 160 
enzymatically active with kinetic parameters very similar with those reported for their extant 161 
human-derived enzymes.2,17,34,37,48–51 The kcat, KM
NADPH and uncoupling values ranged between 162 
0.03-0.32 s-1, 3.5-7.8 µM, and 0.016-0.03 s-1, respectively (Table 1). It was especially noticeable 163 
that the AncFMOs displayed a high affinity towards the coenzyme NADPH and a significantly 164 
higher NADPH consumption rate when a suitable substrate was present. This result is in full 165 
agreement with the canonical catalytic mechanism observed for FMOs and sequence related 166 
flavoprotein monooxygenases (Scheme 1). These features were further demonstrated by stopped-167 
flow kinetic studies. NADPH-reduced AncFMO2 and AncFMO3-6 were found to react rapidly with 168 
oxygen to form a stable and detectable C4alpha-(hydro)peroxyflavin intermediate with its well-169 
defined spectroscopic properties (Figure 2). Based on the steady-state kinetics data, AncFMO5 is 170 
assumed to behave similarly. Collectively, these experiments convincingly demonstrated that our 171 
AncFMO2/3-6/5 enzymes are enzymatically competent and exhibit the typical catalytic features of 172 















































Figure 2. Stopped-flow kinetics studies on AncFMO2 and AncFMO3-6. A: Enzyme reduction 218 
upon the anaerobic addition of NADPH. B: Mixing reduced enzyme with dioxygen (0.13 mM) 219 
reveals the appearance of a peak at 360 nm which is characteristic for a C4a-(hydro)peroxyflavin 220 
intermediate (Scheme 1). C: Mixing reduced enzyme with dioxygen (0.13 mM) and trimethylamine 221 
(1 mM or 0.4 mM for AncFMO2 and 3-6, respectively) reveals again a rapid formation of the C4a-222 
  AncFMO2 AncFMO3-6 
kred (s
-1) 14.6 ± 0.5 0.2 ± 0.03 
k intermediate formation (s-1) 7.4 3.7 
k decay intermediate (s-1) 0.01 ± 0.006 0.01 ± 0.001 
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(hydro)peroxyflavin intermediate which subsequently decays to form the reoxidized flavin species. 223 
D: Dependence of the rate of C4a-(hydro)peroxyflavin formation (A360nm) on varying oxygen 224 
concentrations. The dotted lines correspond to the atmospheric concentration of dioxygen (0.26 225 
mM). For AncFMO2, the observed saturation behavior suggests a binding event taking place before 226 
dioxygen reacts with the reduced flavin. Interestingly, such a saturation behavior was also reported 227 
for pig liver FMO1.52 E: Rates of reduction, C4a-(hydro)peroxyflavin formation, and C4a-228 
(hydro)peroxyflavin decay in the absence of substrate (0.26 mM dioxygen; dotted line on panels D). 229 
 230 
Table 1: Steady state-kinetics. 231 
 
Substratea kcat (s-1) KM (μM) 
Ancient FMOs 
AncFMO2 Methimazole 0.19 ± 0.01 106 ± 22 
Thioanisole 0.3 ± 0.02 6.9 ± 1.6 
Trimethylamine 0.16 ± 0.008 445 ± 74 
NADPH  0.32 ± 0.05 7.8 ± 1.4 
NADPHuncoupling 0.02 ± 0.001 20 ± 5.4 
AncFMO3-6 Methimazole 0.19 ± 0.005 21 ± 2.3 
Thioanisole 0.1 ± 0.008 128 ± 38 
Trimethylamine 0.24 ± 0.01 41 ± 6.3 
NADPH 0.13 ± 0.008 3.5 ± 0.86 
NADPHuncoupling 0.022 ± 0.002 16 ± 5.4 
AncFMO5 Heptan-2-oneb 0.07 ± 0.003 6.36 ± 1.2 
 NADPH 0.06 ± 0.001 6.48 ± 0.38 




NADPHc 0.06 ± 0.16 46 ± 9 
human 
FMO5 
NADPHc 0.197 ± 0.009 59 ± 8 
a Rates were determined by following NADPH consumption (absorbance decrease at 340 nm). The 232 
buffer was composed of 50 mM potassium phosphate (pH 7.5), 250 mM NaCl, 0.05% (v/v) triton 233 
X-100 reduced. The reactions were run at 37 °C. For the determination of the KM of the substrates, 234 
100 M and 50 M NADPH was used for AncFMO2 and AncFMO3-6, and AncFMO5 235 
respectively. For the determination of the KM for NADPH, 1 mM trimethylamine was used as 236 
oxygen-accepting substrate for AncFMO2 and AncFMO3-6, whilst 30 mM of heptan-2-one was 237 
used for AncFMO5. NADPHuncoupling rates were determined in the absence of substrates. The 238 
increase (“burst”) in NADPH consumption rates upon addition of the substrates demonstrate that 239 
the AncFMOs are highly coupled and effectively oxygenate their substrates. 240 
b Heptan-2-one is a typical ketone substrate for the Baeyer-Villiger oxidation catalyzed by FMO5 241 
(Scheme 1). 242 
c The rates for NADPH consumption in the presence and absence of the substrate are the same 243 
because of a high degree of uncoupling in the extant human FMOs. The data for human FMO3 are 244 








AncFMOs crystallize as dimers with extensive membrane binding features 251 
To investigate the role of the AncFMOs in detail, the crystal structures of each AncFMO in the 252 
presence of NADP+ were determined (Figure 3). AncFMO2 was also crystallized in the absence of 253 
NADP+ but, akin to Class B flavin-dependent monooxygenases, no major conformational changes 254 
were observed between the apo- or holo-enzyme crystal structures (Supplementary Figure 3). The 255 
structures were solved at 2.7, 3.0, 2.8, and 2.7 Å resolution for AncFMO2 (without NADP+), 256 
AncFMO2, AncFMO3-6, and AncFMO5 (all including NADP+), respectively (Supplementary 257 
Table 1, Supplementary Figure 4). For the purpose of the structural analysis, it must be highlighted 258 
that the AncFMOs display high sequence identities to their extant human FMO counterparts: 92%, 259 
83%, and 92% for AncFMO2, AncFMO3-6, and AncFMO5 respectively, making them excellent 260 
structural models of human FMOs (Supplementary Figure 5). 261 
Our crystal structures depict the AncFMOs as dimers: they possess an extensive monomer-262 
monomer interface over approximately 2000 Å2 (calculated by the PISA server).53 Furthermore, 263 
their well-conserved FAD and NADP(H) dinucleotide-binding domains are accompanied by two 264 
large trans-membrane helices (one from each monomer) that project outwards, approximately 265 
parallel to the twofold axis (Figure 3A-D). Pairwise structural superpositions of AncFMO2, 266 
AncFMO3-6, and AncFMO5 show that their ordered ~480 C atoms overlap with root-mean-267 
square deviations of less than 1 Å. This result reveals a high degree of structural similarity among 268 
the FMO structures. We additionally notice that the dimerization interface of the AncFMOs is 269 
different from the dimer interfaces exhibited by soluble FMOs (e.g. FMO from Roseovarius 270 
nubinhibens, PDB entry 5IPY; FMO from Methylophaga aminisulfidivorans, PDB entry 2VQ7).  271 
The mammalian FMOs were predicted to contain a highly hydrophobic C-terminal transmembrane 272 
helix (residue 510-532 in AncFMO3-6; Supplementary Figure 5). The crystal structures of 273 
AncFMO2 and AncFMO3-6 perfectly confirmed this prediction as both enzymes possess C-274 
terminal trans-membrane helices that span 30 Å in length and are decorated with many hydrophobic 275 
residues (Figure 3A, 3B and 3D). Of notice, these -helical scaffolds represent the key protein-276 
protein interactions established within the crystal packing (Supplementary Figure 6). High disorder 277 
rendered the C-terminal residues untraceable in the crystal structure of AncFMO5. The 278 
transmembrane helices of AncFMO2 and AncFMO3-6 root themselves deep within the 279 
phospholipid bilayer through a bitopic membrane binding mode, whereby the final C-terminal 280 
residues exit the other side of the membrane. These two helices anchor the protein firmly into the 281 





Figure 3: Crystal structures of the AncFMOs. Crystallographic dimers of AncFMO2, AncFMO3-6 285 
and AncFMO5 are shown in lime green (A), dark magenta (B) and orange (C). FAD and NADP+ 286 
are shown in yellow and cornflower blue, respectively. The orientations of the AncFMOs are 287 
identical, depicting their structures as if they were sitting on the phospholipid bilayer. In A, the 288 
lengths of the trans-membrane helices are portrayed at 35 Å, with the membrane cross-section 289 
indicated with brackets. In C, the membrane-protein interface is indicated by a horizontal dashed 290 
line, mapped with respect to the polar head group of the dodecyl-β-D-maltoside (DDM) detergent. 291 
Additionally, a molecule of HEPES buffer is observed entering the enzyme at the membrane-292 
protein interface. D: Distribution of charge around the surface of AncFMO2, with red, white, and 293 
blue representing negative, neutral, and positive respectively. On rotation about 90°, we see the 294 
large parallel hydrophobic strips across the bottom of the dimer, lined by a ring of positively 295 





It was reported that truncation of the C-terminal helices was insufficient for protein 298 
solubilization.54,55 This indicated that the enzyme possessed additional membrane-binding features. 299 
To understand what elements promote membrane association, the charge distribution on the protein 300 
surface was scrutinized. Intriguingly on the underside of the dimer, two large hydrophobic strips, 301 
about 30 Å in length, extend across the enzyme surface (Figure 3D). These strips are lined by an 302 
extensive ring of positively charged residues. Collectively, these features equip the enzyme for 303 
binding to the membrane surface. The array of hydrophobic residues penetrate, monotopically, into 304 
the phospholipid bilayer and are held in place by the ionic-based interactions introduced between 305 
the negatively charged, polar head group of the phospholipids and the positively charged amino 306 
acids. Serendipitously, in the crystal structures of AncFMO2 and AncFMO5, we were able to 307 
observe the polar head groups of the detergent molecules, CYMAL-6 and dodecyl-β-D-maltoside 308 
(DDM) respectively, that were used for protein solubilisation and crystallisation (Figure 3A, 3C, 309 
3D). These molecules delineate the membrane-enzyme interface and further validates that the 310 
hydrophobic strips monotopically embed within the membrane. These findings rationalize the 311 
extensive membrane binding nature employed for this class of enzymes and corroborates that 312 
truncation of the C-terminal helix alone is not sufficient to facilitate protein solubilization.54 FMOs 313 
employ both bitopic and monotopic membrane-binding features to grapple onto the membrane 314 
effectively and abstract lipophilic substrates from within the membrane. 315 
 316 
An eighty-residue insertion reshapes the active site and promotes membrane association 317 
To comprehend the unique and distinct structural features associated with mammalian FMOs, we 318 
compared them with structurally characterized soluble FMOs. Consistent with Class B flavin-319 
dependent monooxygenases, the AncFMOs have two well-conserved dinucleotide-binding domains 320 
for cofactors FAD (residues 2-154 and 331-442) and NADP(H) (residues 155-213 and 296-330) 321 
respectively, known as the paired Rossmann fold (Supplementary Figure 7A).2,56 Superposition of a 322 
bacterial FMO (PDB: ID 2vq7, SEQ ID: 29%) from Methylophaga sp strain SK1,12 shows a root-323 
mean-square deviation of 1.1 Å over 205 C atom pairs, verifying a strict evolutionary 324 
conservation of the dinucleotide binding domains. However, close inspection of the structures 325 
reveals very substantial differences. In soluble FMOs, the FAD cofactor is exposed to the solvent 326 
and readily accessible by substrates. By contrast, an 80-residue insertion (214-295 in AncFMO3-6; 327 
Supplementary Figure 7B-C) shields the AncFMOs’ active site from the cytosol and creates closed 328 
substrate-binding cavities. This insertion is comprised of a subdomain orchestrated by three small 329 
-helical units that form a ridge-like, triangular fold. Additionally, this subdomain forms the first 330 
half of the hydrophobic strip mentioned above. Despite the FAD and the catalytic-center being 331 
13 
 
buried by the insertion, this subdomain provides a series of tunnels that branch out from the 332 
membrane towards the active site (see below). This finding implies that substrates navigate through 333 
tunnels manufactured by the insertion to access the closed catalytic cavity. 334 
 335 
AncFMO consists of a buried active site and a well conserved NADP(H) binding mode 336 
With the AncFMOs active sites no longer being open clefts like their soluble homologs, we 337 
scrutinized each closely to determine the functions of each residue and whether the mode of 338 
NADP(H) binding is akin to Class B flavin-dependent monooxygenases. Notably, most residues in 339 
the active and NADPH-binding sites are conserved with near-identical conformations (Figure 4A-340 
C). Thr62/Ser62/Thr63 for AncFMO2/3-6/5 respectively, are within hydrogen bonding distance to 341 
the N3 atom of the isoalloxazine ring and orientate the FAD towards the substrate pocket. 342 
Additionally, Asn61/61/62 is observed in all active sites and is strictly conserved among human 343 
FMOs (Supplementary Figure 5). This residue situates close to the C4a of the isoalloxazine ring 344 
(4.6 Å) and is likely fundamental for the stabilization of the flavin-(hydro)peroxide intermediate 345 
(Scheme 1). Consistently, mutating this residue in human FMO3 causes trimethylaminuria, further 346 
verifying its integral role within the active site.12,28 347 
 348 
Figure 4: Active sites of the AncFMOs. The active sites for AncFMO2, AncFMO3-6 and 349 
AncFMO5 are shown in A, B and C, respectively. All three bear a high degree of similarity with 350 
most amino acids being strictly conserved and displaying identical conformations. The differing 351 
residues are as follows: Thr62/Ser62/Thr63; E281/E281/H282; Ile378/Thr378/Ile378 for 352 
AncFMO2/AncFMO3-6/AncFMO5 respectively. AncFMO3-6 also contains a tentatively assigned 353 
14 
 
molecule of dioxygen (OXY). For the sake of comparison, panel D shows the binding of NADP+ to 354 
the active site of phenylacetone monooxygenase, a prototypical class B monooxygenase (PDB code 355 
2ylr). Arg337 is a conserved residue that is essential for the Baeyer-Villiger activity of this and 356 
similar enzymes. 357 
 358 
The binding mode of NADP+ observed in the crystal structures is iconic to Class B flavin-359 
dependent monooxygenases (Figure 4D).4 The overhanging Arg223/223/224 is within hydrogen 360 
bonding distance of the carbonyl derived from the carbamide of NADP+. Additionally, the amino 361 
group of the same carbamide forms a hydrogen bond with the N5 atom of the isoalloxazine ring. 362 
More so, the nicotinamide ring is sterically held in place by a well conserved Asn194/194/195 363 
which acts like a back door for the cofactor (Figure 4A-C). This feature is not uncommon and 364 
portrayed in some soluble FMOs by a protruding tyrosine.12,57,58 The hydroxyl groups of the ribose 365 
forms part of an intricate hydrogen bonding network. The 2’-OH group is within hydrogen bonding 366 
distance of the back-door residue Asn194/194/195 (3.0 Å) in AncFMO3-6 and AncFMO5, and 367 
Glu281 (2.9 Å) in AncFMO2 and AncFMO3-6. Additionally, the conserved Gln373 among the 368 
AncFMOs is within hydrogen-bonding distance of the 3’-OH group. Collectively, these hydrogen 369 
bonds and the steric interactions orientate the nicotinamide and the ribose in a manner characteristic 370 
to this class of enzymes and reiterate a significant role of NADP+ in catalysis, most likely in C4a-371 
(hydro)peroxyflavin formation/stabilization and substrate oxygenation (Scheme 1).12,52,57,59 372 
 373 
A Glu–His mutation in the mammalian specific insertion may promote Baeyer-Villiger oxidation 374 
in FMO5 375 
With AncFMO5 being structurally very similar to the AncFMO2 and AncFMO3-6, but at the same 376 
time functionally divergent, we sought out to clarify what features gave rise to its Baeyer Villiger 377 
oxidation activity. Inspecting the active site alone, the differing mode of action is likely derived 378 
from a Glu-to-His substitution. In AncFMO2 and AncFMO3-6, Glu281, derived from the above-379 
described mammalian FMO-specific 80-residue insertion, points towards the flavin ring. With 380 
positively charged substrates being preferred by FMOs,2 Glu281 is probably deprotonated and 381 
negatively charged within the cavity. In AncFMO5 however, this residue is substituted for His282 382 
which optimally positions the Nɛ-H of its imidazole ring towards the substrate pocket (Figure 4C) 383 
and likely serves as a hydrogen bond donor. This function is commensurate with Baeyer-Villiger 384 
monooxygenases, whereby hydrogen bond-donating residues (i.e. Arg; Figure 4D) are prevalent in 385 
the vicinity of the FAD ring to activate the carbonyl functional group of the substrate for 386 
electrophilic attack by the flavin-peroxy intermediate and stabilize the Criegee intermediate formed 387 
during Baeyer-Villiger oxidation catalysis (Scheme 1).60–62 These observations rationalize the 388 
functional convergence observed among the FMO5 clade and Baeyer-Villiger monooxygenases. To 389 
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probe the importance of His282 in AncFMO5, the H282E mutant was prepared and analyzed. This 390 
revealed that the H282E AncFMO5 mutant fully lost its activity. Analogously, the E281H 391 
AncFMO2 and E281H AncFMO3-6 mutant enzymes were prepared which were found to retain 392 
FMO activity toward thioanisole. Yet, they were not able to perform Baeyer-Villiger oxidations 393 
(Supplementary Table 2). This could be due to the fact that the fine structural and geometric 394 
features for formation and stabilization of the Criegee intermediate (Scheme 1) needs further 395 
mutations, e.g. in the second-shell of active site residues. 396 
 397 
AncFMOs possess a conserved substrate tunnel that branches out towards the membrane 398 
As the mammalian FMOs are notorious for their broad substrate profiles, we conducted extensive 399 
research to elaborate how the substrates navigate through the enzyme using the HOLLOW server.63 400 
The conserved tunnel is roughly perpendicular to the face of the isoalloxazine ring and extends 401 
outwards (approximately 16 Å) towards the membrane, before deviating in multiple directions 402 
(Figure 5). In all three structures, the inner segment of the tunnel features a conserved leucine that 403 
acts as a gate keeper (Leu375 in AncFMO3-6; Figure 5B, lower panel): in an upward position, it 404 
creates a closed cavity at the active site (AncFMO3-6), and in the downward position, it opens the 405 
tunnel to the protein-membrane interface (AncFMO2 and AncFMO5). This leucine is also 406 
conserved in human FMO1-3 and 5, implying an integral role in gating the inner “catalytic” part of 407 
the tunnel and affording a solvent-protected environment for catalysis (Supplementary Figure 5).  408 
The substrates/products penetrate/exit the tunnels through the subdomain found in the 80-residue 409 
insertion. Here, the paths are heavily dictated by the conformations of the residues in and around the 410 
subdomain (Figure 5A-D). Specifically, a few noticeable changes were observed (Figure 6). The 411 
largest conformational difference is seen at residues 337-352 and 338-352 for AncFMO2/3-6 and 412 
AncFMO5 respectively (herein referred to as loop 1). In AncFMO2 and AncFMO5, loop 1 forms a 413 
large arched fold that sits underneath the NADP(H) binding pocket. In AncFMO3-6, loop 1 instead 414 
forms a tightly coiled -helix creating an open cavity below the NADP+ binding pocket. This new 415 
cavity leads to the cytosolic tunnel observed in AncFMO3-6 (Figure 5B). The second difference 416 
observed comprises residues 419-431 for AncFMO2 and AncFMO5 and residues 419-429 for 417 
AncFMO3-6 (loop 2) in the neighborhood of the tunnel entrances. The final differences detected 418 
concern residues 273-282 of AncFMO2 and AncFMO3-6, and 274-283 of AncFMO5 (loop 3). In 419 
AncFMO5, loop 3 features a -helical turn that blocks the cytosolic tunnel observed in AncFMO2 420 
and AncFMO3-6. Moreover, AncFMO5 possesses a shorter -helix in the subdomain which widens 421 
the cavity entrance site. These features have critical implications for the mechanisms of substrate 422 
binding and selectivity in FMOs. On the one hand, these structural variations on surface elements at 423 
16 
 
the tunnel entrances are likely to govern the similar but not identical substrate acceptance of the 424 
FMOs. On the other hand, despite these differences, all three AncFMO structures show that the 425 
tunnels can be accessed by both hydrophilic substrates that predictably diffuse from the cytosol, and 426 
by hydrophobic substrates that likely diffuse from the membrane. Likewise, hydrophilic and 427 
hydrophobic products can diffuse from the active site to the cytosol and to the membrane, 428 
respectively. 429 
Figure 5: Substrate tunnels of the AncFMOs. Upper panels A, B and C portray the tunnels of 430 
AncFMO2, AncFMO3-6 and AncFMO5 respectively, with the protein-membrane interface labeled 431 
as MEM. Lower panels A, B and C, illustrate the directions of the tunnels for AncFMO2, 432 
AncFMO3-6 and AncFMO5 respectively with their directions towards the membrane or the cytosol 433 
depicted by black and green arrows respectively. The residues that block tunnel routes based on 434 
their conformations are shown. AncFMO2 and AncFMO3-6 contains two tunnel exits: one leading 435 
towards the membrane (black arrow) and one to the aqueous environment (green arrow). AncFMO5 436 
contains two tunnels which both lead to membrane (black arrows). Upper panel D displays a 437 
molecule of DDM found above the -helical triad to emphasize the protein-membrane interface in 438 
AncFMO5. Additionally, a molecule of HEPES is present in the tunnel passing below the helix, 439 
demonstrating a substrate accessible pathway. Lower panel D highlights residue Phe232 in 440 
AncFMO5 with respect to gatekeeper Leu375, inferring its vicinity to the FAD and how the change 441 









Figure 6: Structural differences among the AncFMOs. Upper and lower panels describe the 449 
conformational differences observed among the AncFMOs with AncFMO2, AncFMO3-6 and 450 
AncFMO5 depicted in lime green, dark magenta and orange respectively. Loop #1 contains residues 451 
337-352 for AncFMO2 and AncFMO3-6, with resides 338-352 for AncFMO5. Loop #2 contains 452 
residues 419-431 for AncFMO2 and AncFMO5, with residues 419-429 for AncFMO3-6; Loop #3 453 
contains residues 273-282 and 274-283 for AncFMO2 and AncFMO3-6, and AncFMO5 454 
respectively. In the lower panel, a rotation of approximately 45° was imposed to portray the 455 










AncFMOs are thermostable enzymes that are stabilized significantly in the presence of NADP+ 458 
and are reliable models for human FMOs  459 
Allegedly, highly thermostable enzymes are highly prone to crystallization.64 Considering that all 460 
three AncFMOs crystallized, melting temperature (Tm) assays were conducted using the 461 
ThermoFAD technique,65 to investigate the thermal stability of AncFMOs compared to human 462 
FMOs. Remarkably, our AncFMOs in storage buffer conditions (see Materials & Methods) reached 463 
Tms of 60 °C. Comparing AncFMO3-6 and AncFMO5 with human FMO3 and human FMO5 464 
directly, we observed increases of the Tm of up to +22 and +11 °C respectively (Supplementary 465 
Table 3, Supplementary Figure 8).37 Generally, the differences between the AncFMOs and their 466 
respective human equivalents are found dispersed across the protein (Supplementary Figure 9). 467 
These patterns of highly distributed and non-systematic amino acid replacements between ancestral 468 
and extant enzymes validate the notion that AncFMOs are very reliable models for the human 469 
FMOs. Noticeably, at the periphery of the active site, the small Ala232 in human FMO5 is mutated 470 
to a bulky Phe232 in AncFMO5 (Figure 5D, lower panel). This substitution may well allow larger 471 
substrates in human FMO5. Intriguingly, Fiorentini et al. documented that NADP+ has no effect on 472 
the Tm of human FMO5,
37 a result also observed for human FMO3 (Supplementary Figure 8). 473 
However, the melting temperatures of all three AncFMOs increased in the presence of NADP+ by 474 
+17, +7 and +4 °C for AncFMO2, AncFMO3-6 and AncFMO5 respectively (Supplementary Table 475 
3). With AncFMOs exhibiting a low degree of uncoupling, it corroborates that tight binding of 476 
NADP+ is necessary for highly coupled reactions (Table 1; Figure 1). 477 
 478 
Discussion 479 
Our work supports the notion that the number of FMOs in vertebrates significantly increased by 480 
successive gene duplication events, leading to the multiple paralogs observed in mammals today.44 481 
Tetrapods encode for four (amphibians, testudines and birds) or six (mammals) different FMOs, 482 
suggesting defined roles for each of these variants. Analyzing the different paralogs, we observed 483 
that FMO3 and FMO6 followed a common evolutionary path preceded by the diversification of 484 
FMO4, FMO1 and FMO2. FMO5 originated from the earliest gene duplication event and, 485 
intriguingly, is encoded by all the aforementioned terrestrial vertebrates’ classes. With AncFMOs 486 
exhibiting substrate profiles and catalytic rates as their FMO successors, we propose that this class 487 
of enzymes have an evolutionary conserved mode of action. Moreover, two new features are 488 
derived from ancestral sequence reconstruction: (i) increased melting temperatures and (ii) the 489 
stabilizing effect induced by NADP+ (see Supplementary Table 3). With the mutations scattered 490 
across the protein, it is unlikely that individual mutations stabilize the enzyme greatly. Their 491 
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summation however, enhances stability tremendously. Whether this higher thermal stability of the 492 
AncFMOs has a biological meaning remains unclear.66 493 
Our research has resulted in the unveiling of the first structures hitherto of mammalian FMOs. 494 
Together, they demonstrate the extensive membrane-binding features employed by this enzyme 495 
class. Literature had always speculated that the C-terminus was involved in membrane 496 
association,37,54,55,67 but the roles of the large insertions present in human FMOs were ostensibly 497 
more enigmatic. The dimerization observed in the crystal structure is not uncommon to membrane 498 
proteins and is now attributed to mammalian FMOs.58,68 Specifically, the oligomerization state aids 499 
membrane insertion as the protein occupies a larger membrane-surface area.68 The inserted residues 500 
together form a large monotopic binding feature, which constitutively holds the enzyme in the 501 
membrane, ensuring constant uptake and release of substrates and products from and to the 502 
membrane. These molecules are then siphoned through the enzyme via a series of tunnels 503 
implemented by this subdomain. These routes also open to the cytosolic side of the enzyme 504 
structures. Presumably, all FMOs are thereby capable of accepting and expelling soluble 505 
compounds from and into the cytosolic solvent as well as lipophilic compounds from and into the 506 
membrane bilayer.  507 
With the AncFMOs all accommodating very similar active sites, substrate profiles are likely 508 
differentiated by the tunnels penetrating the scaffold. FMO2 is generally known to be slightly more 509 
restrictive in terms of substrate size, mostly metabolizing molecules possessing amino groups 510 
attached to large aliphatic tails.2,69 Whilst, FMO3 and FMO1 are understood to be more 511 
promiscuous, occupying a breadth of substrate sizes.2,18,70 The tunnels hereby depicted do not allow 512 
us to confidently rationalize these phenomena specifically. For example, the high activity of FMO3 513 
towards trimethylamine likely arises from the combination of subtle factors including the 514 
distribution of charged residues, the partition of hydrophobic versus hydrophilic residues at the 515 
entrance and inside the FMO3 tunnel, and the flexibility of the residues that gate tunnel access and 516 
substrate diffusion. Nevertheless, the overall architecture of the catalytic site and of the access 517 
tunnels fully explains the broad substrate scopes of mammalian FMOs. Above all, the catalytic site 518 
promotes the flavin-mediated activation of oxygen through the formation of the flavin-519 
(hydro)peroxide intermediate as observed in soluble FMOs as well as in Baeyer-Villiger 520 
monooxygenases.71,72 After flavin reduction, the nicotinamide-ribose moiety of NADP+ relocates to 521 
give access to the oxygen-reacting C4a atom of the flavin and thereby promote formation of the 522 
flavin-(hydro)peroxide that awaits a substrate to be monooxygenated (Scheme 1). Along these lines, 523 
no elements for the specific recognition of the substrate can be identified. The tunnel and the inner 524 
catalytic cavity of FMOs are rather designed to allow a “controlled” access to the flavin-525 
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(hydro)peroxide without any strict or rigorous binding selectivity. It can easily be envisioned that 526 
the tunnels can adapt themselves depending on the bulkiness of the ligands. The gating elements 527 
(e.g. Leu375) may well seal the active-site cavity when small substrates are bound (Figure 5). 528 
Likewise, the same elements could enable the binding of bulky molecules whose non-reactive 529 
groups extend along the tunnel. Thus, FMOs exhibit typical features of enzymes that broadly 530 
function in xenobiotic detoxification. Their preference for nitrogen- and sulfur-containing substrates 531 
primarily reflects the pronounced reactivity of the flavin-(hydro)peroxide towards these soft-532 
nucleophiles. 533 
In conclusion, we have unveiled the first mammalian flavin-containing monooxygenase structures 534 
through the approach of ancestral sequence reconstruction. Additionally, our work adds to our 535 
understanding of the evolutionary history leading to the expansion of FMOs in terrestrial 536 
vertebrates. The elucidation of three ancient flavin-containing monooxygenases has allowed us to 537 
map the differences between FMOs, providing excellent templates for structure-based drug design. 538 
Furthermore, the thermostable but functionally and structurally conserved proteins delivered by this 539 
method should be seriously and routinely considered as a tool for protein crystallization.  540 
 541 
Materials & Methods 542 
Phylogenetic Inference and Ancestral Sequence Reconstruction. To obtain a robust and 543 
representative phylogeny of FMOs, sequences from the Bacteria and Eukarya were collected by 544 
homology searches using BLAST and HMM profiling. 310 sequences were collected and aligned 545 
with MAFFT v7.73 Best-fit model parameters were obtained by the Akaike information criterion in 546 
ProtTest v3.4. Phylogenies were inferred employing the maximum likelihood method in PhyML 547 
v3.0 or RAxML v0.6.0 with 500/1000 bootstraps and transfer bootstrap expectation (TBE) 548 
subsequently applied.74 As FMOs are not monophyletic, derived clades BVMOs and NMOs were 549 
included in the phylogeny.7,9 Later, the Gnathostomata FMOs phylogeny was constructed for 550 
ancestral sequence reconstruction. To do this, a dataset of 361 sequences was collected including 551 
also a cephalochordate sequence to root the tree according to species tree (Supplementary Data 1).75 552 
Ancestral sequence reconstruction was performed using the maximum likelihood inference method 553 
in PAMLX v.4.9.43,76 Sequences were analyzed using an empirical amino acid substitution model 554 
(model = 3), 4 gamma categories and LG substitution matrix. The posterior probability distribution 555 
of ancestral states at each site was analyzed at nodes AncFMO2, AncFMO3-6 and AncFMO5. Sites 556 
were considered ambiguously reconstructed if alternative states displayed PP >0.2.77 Alternative 557 
sites were found to be 2 for AncFMO2, 15 for AncFMO3-6 and 11 for AncFMO5 (Supplementary 558 
Table 4). These are mostly conservative amino acid substitutions, and after mapping in the crystal 559 
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structures, it was evident that they all lay in the periphery of the protein, not affecting the catalytic 560 
core. 561 
Cloning and Expression of the AncFMOs. Genes were ordered from Genescript containing BsaI 562 
sites at both the 5’ and 3’ ends of the insert. The insert contained overhangs TGGT and CAAG at 563 
the 5’ and 3’ ends respectively to then be inserted into common pBAD-NK destination vectors with 564 
the following modifications: three BsaI sites were eliminated and two were introduced to facilitate 565 
the cloning that incorporated SUMO and 8xHis-tag regions to the N-terminus. Inserts were fused 566 
into the destination vectors through Golder Gate cloning. The sample was prepared with the 567 
following: 75 ng of golden gate entry vector, a molar ratio of 2:1 between insert and vector, BsaI(- 568 
HF) (15 U), 30 WU T4 DNA ligase (15 U), T4 DNA ligase buffer (1x) and Nuclease free water 569 
added to a final volume of 20 μL. During the cloning procedure, a negative control was prepared 570 
with the fragments/inserts omitted. The Golden Gate assembly was conducted in the following 571 
manner, where maximum efficiency was desired: A cycle of 37 °C for 5 mins followed by 16 °C for 572 
10 minutes was repeated 30 times; followed by 55 °C for 10 minutes, 65 °C for a further 20 573 
minutes, finishing with 8 °C for 20 minutes. Once cloned, the plasmids were transformed by heat 574 
shock into E. coli. BL21 cells (25 seconds, 42 °C). Cells from the resulting colonies were pre-575 
inoculated into 100 mL of LB broth containing 100 μg/mL of ampicillin and grown overnight at 37 576 
°C. The cultures were then transferred to 1L Terrific Broth cultures (15 mL) and grown at 24 °C, 577 
rpm 180 for 5 – 6 hours until the OD reached 0.3. The cultures were then induced with a sterilized 578 
arabinose solution (20% w/v), final concentration of 0.02% (w/v) and incubated at 24 °C, 180 rpm 579 
for an additional 24 hours. Cells were then harvested by centrifugation (5000g, 15 mins, 10 °C) 580 
flash frozen in liquid nitrogen and stored at -80 °C. For site-directed mutagenesis, a PCR-reaction 581 
mixture was prepared with 10 µM primer forward and reverse, 100 ng of template DNA, 1.6 % 582 
DMSO, 0.8 mM MgCl2 and 1x Pfu Ultra II Hotstart Master Mix (Agilent). The Quickchange PCR 583 
cycle was performed using the following method: firstly a 5 minute incubation at 95°C, then cycles 584 
(95 °C for 5 minutes - 60 °C for 30 seconds - 72 °C for 6 minutes) were repeated 25 times; followed 585 
by 72 °C for 10 minutes and finishing with 8 °C on hold. The PCR mixture was digested with DpnI 586 
overnight and transformed into E. coli. 587 
Cell Disruption, Extraction, and Purification of AncFMOs. All procedures were carried out in 588 
ice or at 4 °C. Cells (ca. 20 g) were resuspended (1:5) in buffer A (250 mM NaCl, 50 mM KH2PO4, 589 
pH 7.8) and included additional protease inhibitors: phenylmethylsulfonyl fluoride (1 mM), 590 
leupeptin (10 µM), pepstatin (10 μM) and DNase I (5 μg/g of cell paste). The solution was stirred 591 
and incubated at 4 °C for 45 minutes before cell lysis was conducted using sonication or a high-592 
pressure homogenizer. Sonication was conducted using the following conditions: 50 mL solution, 5 593 
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seconds on, 10 seconds off, 1-minute cycles with a total sonication time of 3 minutes using a 594 
microtip (70% amplitude). Cells were passed through a high-pressure homogenizer twice. Lysed 595 
cells were then spun down (1200g, 12 mins, 4 °C) to remove the cell debris. The resultant 596 
supernatant was then centrifuged further (56,000g, 1 hr. 40 mins, 4 °C) to collect the membrane 597 
pellet which was then re-homogenized in buffer A (15 mL,) and centrifuged again (56,000g, 1 hr. 598 
20 mins, 4 °C) to further purify the insoluble material. The resulting pellet was re-homogenized in 599 
buffer A (7 mL) and diluted to a final concentration of 13 mg/mL (assayed using Biuret reagent). 600 
Triton X-100 Reduced (TRX-100-R) (Sigma-Aldrich) was then added to the solution (0.5% (v/v) 601 
final concentration) and mixed overnight at 4 °C. The detergent-solubilized fraction containing the 602 
AncFMOs was then abstracted by collecting the supernatant after centrifugation (56,000g, 1 hr. 20 603 
mins, 4 °C). The supernatant was then transferred to a pre-equilibrated (with buffer A and 0.05% 604 
(v/v) TRX-100-R) gravity column containing a Ni-resin (GE Healthcare). The supernatant was 605 
washed with buffer A, containing 0.05% TRX-100-R, and then with increasing concentrations of 606 
buffer B (50 mM KH2PO4, 500 mM NaCl, 300 mM imidazole, pH 7.8), also containing 0.05% (v/v) 607 
TRX-100-R, in step-by-step fashion: 5 mM imidazole wash, 30 mM imidazole wash and finally a 608 
300 mM imidazole wash, where the protein then eluted. The buffers were then exchanged using a 609 
centrifugal filter unit (50 kDa cut-off) and multiple washes with buffer A with 0.05% (v/v) TRX-610 
100-R. This step was important to remove high concentrations of imidazole employed during the 611 
elution. The protein sample was then concentrated down to a final volume between 500 and 1000 612 
µL. The sample was then mixed with a 6xHis-tagged SUMO protease (1.2 mg/mL) to a volume 613 
ratio of 10:1 respectively and incubated overnight at 4 °C. The sample was then loaded onto an 614 
Akta purification system (GE Healthcare) endowed with a multiwavelength detector (set at 615 
280/370/450 nm) and then onto a nickel-affinity His-trap column (GE Healthcare). The column was 616 
pre-equilibrated with buffer A containing 0.05% (v/v) TRX-100-R, as stated before, with the 617 
proteins eluting out in the presence of 6 mM imidazole derived from buffer B (2%) containing 618 
0.05% (v/v) TRX-100-R. The SUMO-His-tag cleaved protein was then concentrated, and buffer 619 
exchanged using a concentrating centrifugal filter unit (50 kDa cut-off) to a final volume between 620 
250 and 500 µL. The sample was incubated for 1 h with 100 μM FAD at 4 °C and then loaded onto 621 
a gel filtration column (Superdex 200 10/300, GE Healthcare) pre-equilibrated with a storage buffer 622 
(50 mM Tris-HCl pH 8.5 at 4 °C, 10 mM NaCl) and a detergent of choice to obtain a higher degree 623 
of purity (obtained from anatrace). Typically DDM was used (0.03% (w/v) DDM (analytical 624 
grade)), but other detergents were used for crystallization screenings at 3x their respective Critical-625 
Micelle Concentration (CMC). The protein eluted with a very high purity and homogeneity 626 
(evaluated by SDS-page electrophoresis and the shape of the peak in the chromatogram 627 
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respectively) with an elution volume of 10.5 – 11 mL. The sample was concentrated down to 100 628 
µL using a centrifugal filter unit (50 kDa cut-off) with a final concentration ranging from 5 to 30 629 
mg/mL. 630 
Preparation of human FMO3 and human FMO5. Full-length cDNA encoding for Homo sapiens 631 
FMO3 (UniProt P31513) and FMO5 (NCBI accession number: Z47553) were cloned into a 632 
modified pET-SUMO vector (Invitrogen) to allow insertion of a cleavable N-terminal 8xHis-633 
SUMO tag. Expression, cell disruption, extraction, and purification were performed according to 634 
the methods previously described for human FMO5.37  635 
Kinetic Assays of the AncFMOs. Steady-state kinetics assays were performed in duplicates on a 636 
Jasco V-660 spectrophotometer. Enzyme activity of the ancestral proteins was measured by 637 
monitoring NADPH consumption (absorbance at 340 nm, ε340 = 6.22 mM
-1 cm-1 for NADPH). The 638 
buffer used for kinetic analyses was 50 mM potassium phosphate, 250 mM NaCl, 0.05% TRX-100-639 
R (Sigma-Aldrich), pH 7.5. The reaction volumes were 100 μL and contained variable NADPH and 640 
substrate (methimazole, thioanisole, trimethylamine, heptanone) concentrations and 0.01-2.0 μM 641 
enzyme. The spectrophotometer was set at 37 °C and the NADPH and substrate mix were also 642 
incubated at 37 °C for 5 minutes before starting the reaction by adding enzyme. The pH and 643 
temperature conditions were set based on literature studies for a fair comparison with previously 644 
reported properties of mammalian FMOs. 645 
Kinetic Assays of human FMO3. Kinetic assays were performed in duplicate at 25 °C on a Varian 646 
spectrophotometer (Cary 100 Bio) equipped with a thermostatic cell compartment. The apparent KM 647 
for NADPH was measured by varying NADPH concentrations from 20 to 400 μM in aerated 648 
reaction mixtures (150 μL) containing 2.5 μM human FMO3, 50 mM HEPES pH 7.5, 10 mM KCl, 649 
5% (v/v) glycerol, 0.05% (v/v) TRX-100-R. Reactions were followed by monitoring the decrease of 650 
NADPH concentration (decrease in absorbance) at 340 nm (ε340 = 6.22 mM
-1 cm-1 for NADPH). 651 
Rapid Kinetics Analysis of the AncFMOs. Stopped flow experiments were carried out using the 652 
SX20 stopped flow spectrophotometer equipped with either the photodiode array detector or the 653 
single channel photomultiplier (PMT) module (Applied Photophysics, Surrey, UK). Results were 654 
obtained by mixing 50 μL of two solutions in single mixing mode. All solutions were prepared in 655 
50 mM potassium phosphate, 10 mM NaCl and 0.05% TRX-100-R, pH 7.5 at 25 °C. For every 656 
reaction a concentration of 10-15 μM enzyme was used and measurements were done in duplicate. 657 
When needed, the solutions were supplemented with 5.0 mM glucose and the enzyme and/or 658 
substrate solutions were made anaerobic by flushing solutions for 10 minutes with nitrogen, 659 
followed by adding 0.3 μM glucose oxidase (Aspergillus niger, type VII, Sigma-Aldrich) to 660 
consume the left-over oxygen. The monitoring of the reductive half reaction was done by mixing 661 
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the anaerobic enzyme solution with anaerobic buffer containing increasing concentrations of 662 
NAD(P)H (Oriental Yeast Co. LTD.). The rate of flavin reduction was determined by measuring the 663 
decrease of absorbance at 447 nm or 442 nm for AncFMO2 and AncFMO3-6, respectively. In order 664 
to reduce the flavin cofactor in the FMOs for the oxidative half reaction, NADPH was added to an 665 
anaerobic solution containing an equivalent amount of AncFMO. The resulting solution was 666 
incubated on ice until the bleaching of the FAD was complete, indicating complete reduction to 667 
FADH2. The anaerobically reduced FMOs were mixed with air-saturated buffer first and then with 668 
air-saturated buffer containing 1.0 mM or 0.4 mM of trimethylamine, respectively. This allowed us 669 
to follow the spectral changes during the oxidative half-reactions. The C4alpha-(hydro)peroxyflavin 670 
intermediate formation and decay was specifically monitored using the PMT module at 360 nm. For 671 
determining the rates of reoxidation, the reduced enzymes were mixed with buffers containing 672 
different concentrations of dioxygen. The final concentrations of dioxygen (0.13, 0.31, 0.61, 0.96 673 
mM after mixing) were achieved by mixing the anaerobic enzyme solution with (i) air-saturated 674 
buffer; (ii) mixing equal volumes of 100% argon buffer and 100% O2 buffer; (iii) 100% O2 buffer; 675 
(iv) 100% O2 buffer on ice. All solutions were bubbled for ten minutes at room temperature except 676 
the last one which was done on ice. In the case of AncFMO2, in order to confirm its saturating 677 
behaviour, an additional measurement was performed at 0.816 mM of O2 by mixing 100% O2 678 
buffer on ice with 100% argon buffer. 679 
Observed rates (kobs) were determined by fitting traces to exponential functions. All data were 680 
analysed using the software Pro-Data (Applied Photophysics, Surrey, UK) and GraphPad Prism 681 
6.05 (La Jolla, CA, USA). 682 
ThermoFAD Assays.65 A Bio-Rad MiniOpticon Real-Time PCR System was employed to perform 683 
ThermoFAD screenings (temperature gradient 25−70 °C, fluorescence detection every 0.5 °C at 485 684 
± 30 nm excitation and 625 ± 30 nm emission for 5 s). Concentrations were determined using a 685 
molar extinction coefficient of 12 mM-1 cm-1 for the FAD band at 442 nm. Experiments were 686 
performed in triplicate using human FMO5 and the AncFMOs, in the presence or absence of 687 
NADP+. Each sample contained the protein of interest (4 µM), and with or without NADP+ (200 688 
µM), made to a final volume of 20 µL using the storage buffer and incubated in ice for one hour. 689 
Melting temperatures for human FMO3 (0.05% (v/v) TRX-100-R) were performed in duplicates 690 
and diluted to a final concentration of 5 μM in buffer (100 mM) with varying pH values (pH 6-6.5 691 
MES, pH 7-7.5-8 HEPES, pH 8-8.5-9 Bicine, pH 9.5 CHES), KCl concentrations (0-500 mM in 692 
HEPES pH 8), and NADP+ concentrations (5-500 µM in HEPES pH 8, 10 mM KCl, 0.05% (v/v) 693 
TRX-100-R) in an attempt to generate optimal storage buffer conditions. 694 
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Conversions. Conversions were performed using AncFMO2 and AncFMO3-6 and their respective 695 
E281H mutants (Supplementary Table 2). Reaction mixtures (1.0 mL) contained 5.0 mM substrate 696 
(<1% EtOH), 0.10 mM NADPH, 2.0 μM enzyme, 5.0 μM phosphite dehydrogenase, 20 mM 697 
phosphite, 50 mM KPi pH 7.5, 250 mM NaCl and 0.05% (v/v) TRX-100-R. The mixtures were 698 
incubated for 18 hours at 30 °C and subsequently extracted with 1.0 mL ethyl acetate. The organic 699 
phase was passed through anhydrous sulfate magnesium to remove residual water. Analysis was 700 
carried out using a GCMS-QP2010 Ultra (Shimadzu) equipped with a HP-1 column, using electron 701 
ionization MS detection. 702 
Crystallization and Structural Determination of the AncFMOs. Each AncFMO crystallized in a 703 
range of conditions with multiple detergents. Typically, PEG 4000 was optimal for crystallization. 704 
The highest diffracting crystallization conditions for each AncFMO are described below. AncFMO2 705 
(with and without NADP+): 12-15 mg/mL of AncFMO2 (in storage buffer and CYMAL-6 (0.09% 706 
(w/v)) was incubated with crystallization conditions of HEPES buffer (0.1 M, pH 7.5) and PEG 707 
4000 (10%) at 20 °C with a ratio of 1:1 on a sitting drop. Sitting drop was 2 µL after mixing and 708 
contained a reservoir of 1 mL. Prior to crystallization, NADP+ (1 mM final) was incubated with 12-709 
15 mg/mL of AncFMO2 for 1 hour at 4 °C. After two days, large yellow crystals formed. 710 
AncFMO3-6: 12-15 mg/mL of AncFMO3-6 (in storage buffer and DDM (0.03% (w/v)) was 711 
incubated with crystallization conditions of Sodium Acetate buffer (0.1 M, pH 5.5) and PEG 4000 712 
(7.5%) at 20 °C with a ratio of 1:1 on a sitting drop. Sitting drop was 2 µL after mixing and 713 
contained a reservoir of 1 mL. Prior to crystallization, NADP+ (1 mM final) was incubated with 12-714 
15 mg/mL of AncFMO3-6 for 1 hour at 4 °C. After one day, large yellow crystals formed. 715 
AncFMO5: 12 mg/mL of AncFMO5 (in storage buffer and DDM (0.03% (w/v)) was incubated with 716 
crystallization conditions of HEPES buffer (0.1 M, pH 6.9) and PEG 4000 (9%) at 20 °C with a 717 
ratio of 1:1 on a sitting drop. Sitting drop was 2 µL after mixing and contained a reservoir of 1 mL. 718 
Prior to crystallization, NADP+ (1 mM final) was incubated with 12-15 mg/mL of AncFMO5 for 1 719 
hour at 4 °C. After one day, large yellow hexagon shaped crystals formed. During crystal fishing, a 720 
cryo-protectant was prepared containing modified crystallizations conditions with 20% glycerol and 721 
PEG 4000 (15%).  722 
Data were collected at the European Synchrotron Radiation Facility (Grenoble, France) and the 723 
Swiss Light Source, (Villigen, Switzerland) and processed with the XDS78 and CCP4 packages.79 724 
Aimless was used to merge the observations into average densities (Supplementary Table 1). 725 
STARANISO was additionally used for AncFMO2 which suffered greatly from anisotropy.80,81 The 726 
phase problem was solved by Molecular Replacement using a recently solved insect FMO 727 
(PDB:5nmw)82 as a search model, and then AncFMO2 for the proceeding AncFMOs, using Phaser 728 
26 
 
and Molrep.83 The phases were greatly improved by density averaging with DM.79,84 Model 729 
Building and Refinement were then conducted using COOT,85 Buccaneer,79 and Refmac586 730 
respectively (Supplementary Table 1). Figures were then generated using UCSF Chimera,87 731 
PyMOL (DeLano Scientific; www.pymol.org) and CCP4mg.79 732 
 733 
Acknowledgements 734 
The research for this work has received funding from the European Union’s Horizon 2020 research 735 
and innovation programme under the Marie Skłodowska-Curie grant agreement No 722390 and 736 
ANPCyT (Argentina) PICT 2016-2839 to MLM. MLM is a member of the Research Career of 737 
CONICET, Argentina. Authors thank Dr. Maximiliano Juri Ayub for his valuable comments and 738 
contributions on the manuscript  739 
 740 
Author Contributions 741 
All listed authors performed experiments and analyzed data: CRN generated purification protocols, 742 
crystallized the AncFMOs, collected the corresponding datasets at ESRF and SLS facilities, 743 
performed structural analysis and elucidated the AncFMO structures. GB and CRN performed 744 
golden gate cloning to insert the AncFMO genes into their respective vectors, designed by GB. GB 745 
carried out mutagenesis and extensive kinetic analysis and validated the substrate profiles using 746 
stopped-flow UV/Vis spectroscopy and GCMS for each AncFMO. MLM conducted thorough 747 
evolutionary analyses and performed ancestral sequence reconstruction obtaining AncFMO protein 748 
sequences. CRN, GB and MLM prepared the figures. CRN wrote the manuscript and edited by AM, 749 
MWF and MLM. All authors provided critical feedback and helped shape the research, analysis and 750 
manuscript. AM and MWF conceived the original idea.  751 
 752 
Declaration of Interest 753 
The authors declare no conflict of interest. 754 
 755 
Data availability  756 
Coordinates and structure factors have been deposited with the Protein Data Bank with accession 757 
codes 6SEM (AncFMO2), 6SF0 (AncFMO2 in complex with NADP+), 6SE3 (AncFMO3-6), 6SEK 758 
(AncFMO5). All other data is available from the authors upon reasonable request. 759 
 760 
References 761 
1. Jakoby, W. B. & Ziegler, D. M. The enzymes of detoxication. J. Biol. Chem. 265, 20715–762 
20718 (1990). 763 
27 
 
2. Krueger, S. K. & Williams, D. E. Mammalian flavin-containing monooxygenases: 764 
Structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol. Ther. 765 
106, 357–387 (2005). 766 
3. Cruciani, G. et al. Flavin monooxygenase metabolism: Why medicinal chemists should 767 
matter. J. Med. Chem. 57, 6183–6196 (2014). 768 
4. Huijbers, M. M. E., Montersino, S., Westphal, A. H., Tischler, D. & Van Berkel, W. J. H. 769 
Flavin dependent monooxygenases. Arch. Biochem. Biophys. 544, 2–17 (2014). 770 
5. Ziegler, D. M. Flavin-containing monooxygenases: enzymes adapted for multisubstrate 771 
specificity. Trends Pharmacol. Sci. 11, 321–324 (1990). 772 
6. Cashman, J. R. Some distinctions between flavin-containing and cytochrome P450 773 
monooxygenases. Biochem. Biophys. Res. Commun. 338, 599–604 (2005). 774 
7. Mascotti, M. L., Lapadula, W. J. & Ayub, M. J. The origin and evolution of Baeyer - Villiger 775 
Monooxygenases (BVMOs): An ancestral family of flavin monooxygenases. PLoS One 10, 776 
1–16 (2015). 777 
8. D. M. Ziegler & Pettit, F. H. Formation of an intermediate N-oxide in the oxidative 778 
demethylation of N,N-dimethylanaline catalyzed by liver microsomes. Biochem. Biophys. 779 
Res. Commun. 15, 188–193 (1964). 780 
9. Mascotti, M. L., Juri Ayub, M., Furnham, N., Thornton, J. M. & Laskowski, R. A. Chopping 781 
and Changing: the Evolution of the Flavin-dependent Monooxygenases. J. Mol. Biol. 428, 782 
3131–3146 (2016). 783 
10. Cashman, J. R. & Zhang, J. Human Flavin-Containing Monooxygenases. Annu. Rev. 784 
Pharmacol. Toxicol. 46, 65–100 (2006). 785 
11. Romero, E., Castellanos, J. R. G., Gadda, G., Fraaije, M. W. & Mattevi, A. The same 786 
substrate, many reactions: oxygen activation in flavoenzymes. Chem. Rev. 118, 1742-1769 787 
(2017). 788 
12. Alfieri, A., Malito, E., Orru, R., Fraaije, M. W. & Mattevi, A. Revealing the moonlighting 789 
role of NADP in the structure of a flavin-containing monooxygenase. Proc. Natl. Acad. Sci. 790 
105, 6572–6577 (2008). 791 
13. Zhang, J. QUANTITATIVE ANALYSIS OF FMO GENE mRNA LEVELS IN HUMAN 792 
TISSUES. Drug Metab. Dispos. 34, 19–26 (2005). 793 
14. Dolphin, C. T., Cullingford, T. E., Shephard, E. A., Smith, R. L. & Phillips, I. R. Differential 794 
developmental and tissue-specific regulation of expression of the genes encoding three 795 
members of the flavin-containing monooxygenase family of man, FMO1, FMO3 and FMO4. 796 
Eur. J. Biochem. 235, 683–689 (1996). 797 
15. McCombie, R. R., Dolphin, C. T., Povey, S., Phillips, I. R. & Shephard, E. A. Localization of 798 
human flavin-containing monooxygenase genes FMO2 and FMO5 to chromosome 1q. 799 
Genomics 34, 426–429 (1996). 800 
16. Hernandez, D., Janmohamed, A., Chandan, P., Phillips, I. R. & Shephard, E. A. Organization 801 
and evolution of the flavin-containing monooxygenase genes of human and mouse. 802 
Pharmacogenetics 14, 117–130 (2004). 803 
17. Fiorentini, F. et al. Baeyer-Villiger Monooxygenase FMO5 as Entry Point in Drug 804 
Metabolism. ACS Chem. Biol. 12, 2379–2387 (2017). 805 
18. Poulsen, L. L. & Ziegler, D. M. Multisubstrate flavin-containing monooxygenases: 806 
applications of mechanism to specificity. Chem. Biol. Interact. 96, 57–73 (1995). 807 
19. Henderson, M. C., Krueger, S. K., Siddens, L. K., Stevens, J. F. & Williams, D. E. S-808 
oxygenation of the thioether organophosphate insecticides phorate and disulfoton by human 809 
lung flavin-containing monooxygenase 2. Biochem. Pharmacol. 68, 959–967 (2004). 810 
20. Cashman, J. R. Role of flavin-containing monooxgenase in drug development. Expert Opn. 811 
Drug Metab. Toxicol. 4, 1507–1521 (2008). 812 
21. Siddens, L. K., Krueger, S. K., Henderson, M. C. & Williams, D. E. Mammalian flavin-813 
containing monooxygenase (FMO) as a source of hydrogen peroxide. Biochem. Pharmacol. 814 
28 
 
89, 141–147 (2014). 815 
22. Li, C. Y. et al. Structural mechanism for bacterial oxidation of oceanic trimethylamine into 816 
trimethylamine N-oxide. Mol. Microbiol. 103, 992–1003 (2017). 817 
23. Miao, J. et al. Flavin-containing monooxygenase 3 as a potential player in diabetes-818 
associated atherosclerosis. Nat. Commun. 6, 1–10 (2015). 819 
24. Krueger, S. K. et al. GENETIC POLYMORPHISMS OF FLAVIN- CONTAINING 820 
MONOOXYGENASE (FMO). 34, 523–532 (2002). 821 
25. Dolphin, C. T., Janmohamed, A., Smith, R. L., Shephard, E. A. & Phillips, I. R. Compound 822 
heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FM03) 823 
gene in patients with fish-odour syndrome. Pharmacogenetics 10, 799–807 (2000). 824 
26. Veeravalli, S. et al. Effect of flavin-containing monooxygenase genotype, mouse strain, and 825 
gender on trimethylamine N-oxide production, plasma cholesterol concentration, and an 826 
index of atherosclerosis. Drug Metab. Dispos. 46, 20–25 (2018). 827 
27. Phillips, I. R. & Shephard, E. A. Flavin-containing monooxygenases: mutations, disease and 828 
drug response. Trends Pharmacol. Sci. 29, 294–301 (2008). 829 
28. Hernandez, D. et al. Trimethylaminuria and a human FMO3 mutation database. Hum. Mutat. 830 
22, 209–213 (2003). 831 
29. Dolphin, C. T., Janmohamed, A., Smith, R. L., Shephard, E. A. & Phillips,  lan R. Missense 832 
mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour 833 
syndrome. Nat. Genet. 17, 491–494 (1997). 834 
30. Lang, D. H. et al. Isoform specificity of trimethylamine N-oxygenation by human flavin-835 
containing monooxygenase (FMO) and P450 enzymes Selective catalysis by fmo3. Biochem. 836 
Pharmacol. 56, 1005–1012 (1998). 837 
31. Hodgson, E., Rose, R. L., Cao, Y., Dehal, S. S. & Kupfer, D. Flavin-containing 838 
monooxygenase isoform specificity for the N-oxidation of tamoxifen determined by product 839 
measurement and NADPH oxidation. J. Biochem. Mol. Toxicol. 14, 118–120 (2000). 840 
32. Mushiroda, T., Douya, R., Takahara, E. & Nagata, O. The involvement of flavin-containing 841 
monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic 842 
agent: Comparison with cisapride and mosapride citrate. Drug Metab. Dispos. 28, 1231–843 
1237 (2000). 844 
33. Shephard, E. A. & Phillips, I. R. The potential of knockout mouse lines in defining the role 845 
of flavin-containing monooxygenases in drug metabolism. Expert Opin. Drug Metab. 846 
Toxicol. 6, 1083–1094 (2010). 847 
34. Krueger, S. K., VanDyke, J. E., Williams, D. E. & Hines, R. N. The role of flavin-containing 848 
monooxygenase (FMO) in the metabolism of tamoxifen and other tertiary amines. Drug 849 
Metab. Rev. 38, 139–147 (2006). 850 
35. Veeramah, K. R. et al. The potentially deleterious functional variant flavin-containing 851 
monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa. Pharmacogenet. 852 
Genomics 18, 877–886 (2008). 853 
36. Dolphin, C. T. et al. The flavin-containing monooxygenase 2 gene (FMO2) of humans, but 854 
not of other primates, encodes a truncated, nonfunctional protein. J. Biol. Chem. 273, 30599–855 
30607 (1998). 856 
37. Fiorentini, F. et al. Biocatalytic Characterization of Human FMO5: Unearthing Baeyer-857 
Villiger Reactions in Humans. ACS Chem. Biol. 11, 1039–1048 (2016). 858 
38. Leiser, S. F. et al. Promotes Longevity and Health Span. Science. 350, 1375–1378 (2015). 859 
39. Warrier, M. et al. The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central 860 
Regulator of Cholesterol Balance. Cell Rep. 10, 326–338 (2015). 861 
40. Gonzalez Malagon, S. G. et al. The phenotype of a knockout mouse identifies flavin-862 
containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing. Biochem. 863 
Pharmacol. 96, 267–277 (2015). 864 
41. Scott, F. et al. Identification of flavin-containing monooxygenase 5 (FMO5) as a regulator of 865 
29 
 
glucose homeostasis and a potential sensor of gut bacteria. Drug Metab. Dispos. 45, 982–989 866 
(2017). 867 
42. Risso, V. A., Sanchez-Ruiz, J. M. & Ozkan, S. B. Biotechnological and protein-engineering 868 
implications of ancestral protein resurrection. Curr. Opin. Struct. Biol. 51, 106–115 (2018). 869 
43. Hochberg, G. K. A. & Thornton, J. W. Reconstructing Ancient Proteins to Understand the 870 
Causes of Structure and Function. Annu. Rev. Biophys. 46, 247–269 (2017). 871 
44. Hao, D. C., Chen, S. L., Mu, J. & Xiao, P. G. Molecular phylogeny, long-term evolution, and 872 
functional divergence of flavin-containing monooxygenases. Genetica 137, 173–187 (2009). 873 
45. Hines, R. N. Alternative Processing of the Human FMO6 Gene Renders Transcripts 874 
Incapable of Encoding a Functional Flavin-Containing Monooxygenase. Mol. Pharmacol. 875 
62, 320–325 (2002). 876 
46. Kumar, S., Stecher, G., Suleski, M. & Hedges, S. B. TimeTree: A Resource for Timelines, 877 
Timetrees, and Divergence Times. Mol. Biol. Evol. 34, 1812–1819 (2017). 878 
47. Grantham, R. Amino acid difference formula to help explain protein evolution. Science. 185, 879 
862–864 (1974). 880 
48. Krueger, S. K. et al. Characterization of sulfoxygenation and structural implications of 881 
human flavin-containing monooxygenase isoform 2 (FMO2.1) variants S195L and N413K. 882 
Drug Metab. Dispos. 37, 1785–1791 (2009). 883 
49. Overby, L. H., Carver, G. C. & Philpot, R. M. Quantitation and kinetic properties of hepatic 884 
microsomal and recombinant flavin-containing monooxygenases 3 and 5 from humans. 885 
Chem. Biol. Interact. 106, 29–45 (1997). 886 
50. Ripp, S. L., Itagaki, K., Philpot, R. M. & Elfarra, A. A. Methionine S-oxidation in human 887 
and rabbit liver microsomes: Evidence for a high-affinity methionine S-oxidase activity that 888 
is distinct from flavin-containing monooxygenase 3. Arch. Biochem. Biophys. 367, 322–332 889 
(1999). 890 
51. Lin, J. & Cashman, J. R. N-oxygenation of phenethylamine to the trans-oxime by adult 891 
human liver flavin-containing monooxygenase and retroreduction of phenethylamine 892 
hydroxylamine by human liver microsomes. J. Pharmacol. Exp. Ther. 282, 1269–1279 893 
(1997). 894 
52. Beaty, N. B. & Ballou, D. P. The reductive half-reaction of liver microsomal FAD-895 
containing monooxygenase. J. Biol. Chem. 256, 4611–4618 (1981). 896 
53. Krissinel, E. Stock-based detection of protein oligomeric states in jsPISA. Nucleic Acids Res. 897 
43, W314–W319 (2015). 898 
54. Geier, M. et al. Human FMO2-based microbial whole-cell catalysts for drug metabolite 899 
synthesis. Microb. Cell Fact. 14, 1–10 (2015). 900 
55. Korsmeyer, K. K. et al. N-glycosylation of pig flavin-containing monooxygenase form 1: 901 
Determination of the site of protein modification by mass spectrometry. Chem. Res. Toxicol. 902 
11, 1145–1153 (1998). 903 
56. Wierenga, R. K., De Maeyer, M. C. H. & Hoi, W. G. J. Interaction of Pyrophosphate 904 
Moieties with α-Helixes in Dinucleotide Binding Proteins. Biochemistry 24, 1346–1357 905 
(1985). 906 
57. Orru, R., Torres Pazmiño, D. E., Fraaije, M. W. & Mattevi, A. Joint functions of protein 907 
residues and NADP(H) in oxygen activation by flavin-containing monooxygenase. J. Biol. 908 
Chem. 285, 35021–35028 (2010). 909 
58. Lončar, N. et al. Characterization of a thermostable flavin-containing monooxygenase from 910 
Nitrincola lacisaponensis (NiFMO). Appl. Microbiol. Biotechnol. 103, 1755–1764 (2019). 911 
59. Fürst, M. J., Fiorentini, F. & Fraaije, M. W. Beyond active site residues: overall structural 912 
dynamics control catalysis in flavin-containing and heme-containing monooxygenases. Curr. 913 
Opin. Struct. Biol. 59, 29–37 (2019). 914 
60. Romero, E., Castellanos, J. R. G., Mattevi, A. & Fraaije, M. W. Characterization and Crystal 915 
Structure of a Robust Cyclohexanone Monooxygenase. Angew. Chemie - Int. Ed. 55, 15852–916 
30 
 
15855 (2016). 917 
61. Torres Pazmiño, D. E., Baas, B. J., Janssen, D. B. & Fraaije, M. W. Kinetic mechanism of 918 
phenylacetone monooxygenase from Thermobifida fusca. Biochemistry 47, 4082–4093 919 
(2008). 920 
62. Criegee, R. Die Umlagerung der Dekalin‐peroxydester als Folge von kationischem 921 
Sauerstoff. Justus Liebigs Ann. Chem. 560, 127–135 (1948). 922 
63. Ho, B. K. & Gruswitz, F. HOLLOW: Generating accurate representations of channel and 923 
interior surfaces in molecular structures. BMC Struct. Biol. 8, 1–6 (2008). 924 
64. Gumulya, Y. et al. Engineering highly functional thermostable proteins using ancestral 925 
sequence reconstruction. Nat. Catal. 1, 878–888 (2018). 926 
65. Forneris, F., Orru, R., Bonivento, D., Chiarelli, L. R. & Mattevi, A. ThermoFAD, a 927 
Thermofluor®-adapted flavin ad hoc detection system for protein folding and ligand binding. 928 
FEBS J. 276, 2833–2840 (2009). 929 
66. Wheeler, L. C., Lim, S. A., Marqusee, S. & Harms, M. J. The thermostability and specificity 930 
of ancient proteins. Curr. Opin. Struct. Biol. 38, 37–43 (2016). 931 
67. Lawton, M. P. & Philpot, R. M. Functional characterization of flavin-containing 932 
monooxygenase 1B1 expressed in Saccharomyces cerevisiae and Escherichia coli and 933 
analysis of proposed FAD- and membrane-binding domains. J. Biol. Chem. 268, 5728–5734 934 
(1993). 935 
68. Allen, K. N., Entova, S., Ray, L. C. & Imperiali, B. Monotopic Membrane Proteins Join the 936 
Fold. Trends Biochem. Sci. 44, 7–20 (2019). 937 
69. Nagata, T., Williams, D. E. & Ziegler, D. M. Substrate Specificities of Rabbit Lung and 938 
Porcine Liver Flavin-Containing Monooxygenases: Differences due to Substrate Size. Chem. 939 
Res. Toxicol. 3, 372–376 (1990). 940 
70. Young Mi Kim & Ziegler, D. M. Size limits of thiocarbamibes accepted as substrates by 941 
human flavin-containing monooxygenase 1. Drug Metab. Dispos. 28, 1003–1006 (2000). 942 
71. Beaty, N. B. & Ballou, D. P. Transient Kinetic Study of Liver. J. Biol. Chem. 255, 3817–943 
3819 (1980). 944 
72. Beaty, N. B. & Ballou, D. P. The Oxidative Half-reaction of Liver Microsomal FAD-945 
containing Monooxygenase. J. Biol. Chem. 256, 4619–4625 (1981). 946 
73. Katoh, K., Rozewicki, J. & Yamada, K. D. MAFFT online service: multiple sequence 947 
alignment, interactive sequence choice and visualization. Brief. Bioinform. 1–7 (2017).  948 
74. Lemoine, F. et al. Renewing Felsenstein’s phylogenetic bootstrap in the era of big data. 949 
Nature 556, 452–456 (2018). 950 
75. Hug, L. A. et al. A new view of the tree of life. Nat. Microbiol. 1, 1–6 (2016). 951 
76. Yang, Z. PAML 4: Phylogenetic Analysis by Maximum Likelihood. Mol. Biol. Evol. 24, 952 
1586–1591 (2007). 953 
77. Siddiq, M. A., Loehlin, D. W., Montooth, K. L. & Thornton, J. W. Experimental test and 954 
refutation of a classic case of molecular adaptation in Drosophila melanogaster. Nat. Ecol. 955 
Evol. 1, 1–6 (2017). 956 
78. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially 957 
unknown symmetry land cell constants. J. Appl. Crystallogr. 26, 795–800 (1993). 958 
79. Project, C. C. The CCP4 suite: Programs for protein crystallography. Acta Crystallogr. Sect. 959 
D Biol. Crystallogr. 50, 760–763 (1994). 960 
80. Tickle, I. J. et al. Staraniso. Glob. Phasing Ltd (2018). 961 
81. Evans, P. R. & Murshudov, G. N. How good are my data and what is the resolution? Acta 962 
Crystallogr. Sect. D Biol. Crystallogr. 69, 1204–1214 (2013). 963 
82. Kubitza, C. et al. Crystal structure of pyrrolizidine alkaloid N-oxygenase from the 964 
grasshopper Zonocerus variegatus. Acta Crystallogr. Sect. D Struct. Biol. 74, 422–432 965 
(2018). 966 




84. Krissinel, E. & Henrick, K. Secondary-structure matching (SSM), a new tool for fast protein 969 
structure alignment in three dimensions. Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 970 
2256–2268 (2004). 971 
85. Jung, W. S., Singh, R. K., Lee, J. K. & Pan, C. H. Crystal Structure and Substrate Specificity 972 
of D-Galactose-6-Phosphate Isomerase Complexed with Substrates. PLoS One 8, 2–11 973 
(2013). 974 
86. Murshudov, G. N., Vagin, A. A. & Dodson, E. J. Refinement of macromolecular structures 975 
by the maximum-likelihood method. Acta Crystallogr. Sect. D Biol. Crystallogr. 53, 240–976 
255 (1997). 977 
87. Pettersen, E. F. et al. UCSF Chimera - a visualization system for exploratory research and 978 
analysis. J. Comput. Chem. 25, 1605–12 (2004). 979 
 980 
 981 
  982 
32 
 
Supplementary Information 983 
 984 
Ancestral Sequence Reconstruction Unveils the Structural Basis of Catalysis and 985 
Membrane Binding in Mammalian Flavin-Containing Monooxygenases 986 
 987 
Callum R. Nicoll1, Gautier Bailleul2, Filippo Fiorentini1, 988 
María Laura Mascotti3,*, Marco W. Fraaije2,* and Andrea Mattevi1,* 989 
 990 
1 Department of Biology and Biotechnology “Lazzaro Spallanzani”, University of Pavia, via Ferrata 991 
9, 27100 Pavia, Italy 992 
2 Laboratory of Biochemistry, Groningen Biomolecular Sciences and Biotechnology Institute, 993 
University of Groningen, Nijenborgh 4, 9747 AG Groningen, The Netherlands 994 
3 IMIBIO-SL CONICET, Facultad de Química Bioquímica y Farmacia, Universidad Nacional de 995 
San Luis, Ejército de  los Andes 950, San Luis D5700HHW, Argentina 996 
 997 
*Correspondence to María Laura Mascotti, Marco Fraaije, Andrea Mattevi 998 
E-mail: mlmascotti@unsl.edu.ar, m.w.fraaije@rug.nl, andrea.mattevi@unipv.it 999 





Supplementary Figure 1: Full phylogeny of FMOs. Tree was constructed in PhyML v3.0, 500 1003 
bootstraps were run, and best-fit model parameters were obtained with ProtTest v3.4. The employed 1004 
multiple sequence alignement was trimmed in single sequence extensions and contained 341 taxa 1005 
and 501 sites. Tree topology was analyzed according to Class B flavoprotein monooxygenases 1006 
phylogeny. As FMOs are paraphyletic (i.e. they do not display a single origin), derived clades are 1007 
shown collapsed: Baeyer-Villiger monooxygenases (yellow) and N-hydroxylating monooxygenases 1008 
(deep teal). FMOs are shown in black branches and monophyletic clades according to organism 1009 
classes are highlighted as follows: Bacteria (cyan), plants (green), vertebrates (red), arthropods 1010 
(orange), and fungi (blue). Statistical support (BS >50) at major divergence points is labeled at the 1011 






Supplementary Figure 2: Vertebrates phylogeny of FMOs. Tree was constructed in RAxML 1014 
v0.6.0, 1000 bootstraps were run and best-fit model parameters were obtained with ProtTest v3.4. 1015 
Bootstrap transfer was applied and TBE values are shown at the nodes. The employed MSA was 1016 
trimmed in single sequence extensions and contained 361 taxa and 569 sites. Clades are collapsed 1017 
and colored according to tetrapods classes: mammalia (magenta), aves (light orange), amphibia 1018 
(green) and testudines (teal). Actinopterygii, coelacanthimorpha and chondrichthyes  (all jawed 1019 
vertebrates) and the cephalochordate sequence in the root are shown in black. Mammalian FMO 1020 
clades are marked inside the clades. The FMOs explosion concordant with  the emergence of 1021 
terrestrial vertebrates (tetrapods, 352 mya) on the left. The three ancestral nodes that were 1022 
experimentally characterized are ploted at the nodes and labelled with yellow squares. The tree was 1023 
prepared in Figtree v1.4.2. Accession codes to sequences can be found in Supplementary Data 1. 1024 




Supplementary Figure 3: Crystal Structure of AncFMO2 in the absence of NADP+ (green) 1027 
superposed to the structure bound to NADP+ (dark green). AncFMO2 crystallizes in an identical 1028 
manner with or without NADP+. The root-mean-square deviation between the native AncFMO2 and 1029 
its NADP+ complex is 0.23 Å over 530 C atom pairs. The orientation of the dimer depicts the 1030 









Supplementary Figure 4: Electron density maps of the AncFMOs. Structure determination was 1038 
greatly facilitated by density averaging because the asymmetric unit of the crystals of AncFMO2, 1039 
AncFMO3-6, AncFMO5 contain four, six, and two protein molecules. The depicted 2Fo-Fc maps 1040 
were calculated by averaging the electron density maps obtained after molecular replacement 1041 
(shown in blue). A: AncFMO2 shown in lime green, without NADP+. B: AncFMO2 shown in lime 1042 
green, with NADP+. C: AncFMO3-6 shown in dark magenta, with NADP+. D: AncFMO5 shown in 1043 
dark orange, with NADP+. Cofactors FAD and NADP+ are shown in yellow and cornflower blue 1044 











Supplementary Figure 5: Structure based sequence alignment using ESPript 3.0. The alignment 1052 
was generated by using AncFMO3-6 pdb structure as input file and inserting the Ancestral FMO 1053 







Supplementary Figure 6: The crystal packing of AncFMO2 forms multiple planes of soluble 1059 
dimer-dimer interactions that extend across the lattice. The asymmetric unit is depicted by the four 1060 
differently coloured monomer units of dark yellow, dark red, dark green and dark blue. In between 1061 
each plane, we see multiple trans-membrane helices projecting upwards and downwards from each 1062 

















Supplementary Figure 7: Topological features of the mammalian FMOs. A: Highly conserved 1078 
NADP(H) and FAD dinucleotide binding domains that are observed in all FMOs. B: The 1079 
characteristic 80-residue insertion (residues 214-295 in AncFMO3-6) that covers the FAD and 1080 
binds to the membrane monotopically through an alpha helical triad. C: The additional C-terminal 1081 
(residues 443-528) that orchestrates both monotopic and bitopic membrane binding features through 1082 




























  1108 
Supplementary Figure 8: NADPH oxidase activity and Melting temperature of hFMO3. A: 1109 
NADPH consumption was not altered by the presence of substrate and so a Michaelis-Menten curve 1110 
was plotted at differing NADPH concentrations. The KM and kcat for NADPH were determined at 46 1111 
± 9 µM and 0.06 ± 0.16 s-1, respectively. B: Extensive buffer screenings for hFMO3 resulted in a 1112 
maximum melting temperature of 44.5 °C (with and without 200 M NADP+ in the upper and 1113 
lower curves, respectively) in buffer conditions of 100 mM HEPES pH 7.5, 10 mM KCl and 0.05% 1114 












































Supplementary Figure 9: Differing residues between AncFMOs and hFMOs. The upper and low 1156 
panels display the structures  in two orientations. The changes exhibited by AncFMO2, AncFMO3-1157 
6 and AncFMO5 compared to hFMOs are shown in lime green, dark magenta and orange, 1158 
respectively. A close systematic analysis of the changes does not reveal any clear pattern of amino 1159 
acid substitutions. Most are localised in the membrane-binding regions, implying that the enzyme 1160 
can undergo multiple mutations in these parts of the protein as long as the hydrophobic nature of the 1161 
side chains is conserved. This finding is further corroborated by the sequence alignment of the 1162 
hFMOs and the AncFMOs sequences, with the sequences at the subdomains and C-termini, varying 1163 
substantially (Supplementary Figure 5). The mutations however, are bereft in the FAD and 1164 
NADP(H) binding domains, describing well-conserved sequence motifs among FMOs. 1165 
Furthermore, the residues inside the enzyme and more importantly, lining the tunnels, are also well 1166 
conserved. Only one overwhelming change in the core of the enzyme is observed in AncFMO5 as 1167 





Supplementary Table 1: Crystallographic table for structures AncFMO2, AncFMO3-6 and 1171 
AncFMO5 complexed with or without NADP+.  1172 
 
          AncFMO2 without NADP+ AncFMO2 with NADP+ AncFMO3-6          AncFMO5 
 
Aimless Staraniso Aimless Staraniso Aimless Aimless 
PDB codes 6SEM 6SF0 6SE3 6SEK 
Resolution Range 48.395 - 2.749 (2.937 - 2.749) 138.06 - 3.01 (3.34 - 3.01) 49.30 - 2.80 (2.85 - 
2.80) 
49.89 - 2.70 (2.82 
- 2.70) 
Space Group C21 C21 P3121 P22121 
Unit Cell (Å, °) 152.96 147.78 144.93 
=96.91 








Total Reflections 232952 
(12654) 
145667 (6653) 178736 (15850) 109279 (7605) 2621815 (133377) 258133 (31923) 
Unique Reflections 77919 
(4332) 
48490 (2425) 51884 (4527) 32052 (2290) 129389 (6372) 38832 (4655) 
Multiplicity 3.0 (2.9) 3.0 (2.7) 3.4 (3.5) 3.4 (3.3) 20.3 (20.9) 6.6 (6.9) 
Completeness (%) 99.1 (98.0) 58.3 (16.2) 99.4 (99.9) 52.1 (13.9) 100.0 (99.9) 99.8 (99.9) 
Completeness 
ellipsoidal (%) 
- 93.6 (76.9) - 92.4 (64.1) - - 
Mean I/sigma (I) 8.8 (0.3) 13.7 (1.3) 3.3 (0.4) 5.3 (1.5) 14.3 (1.3) 9.9 (0.8) 
R-merge 0.080 
(3.85) 
0.054 (0.85) 0.169 (2.37) 0.145 (0.74) 0.235 (2.88) 0.11 (2.19) 
















17542 26169 8329 




0.008 0.010 0.007 




1.310 1.530 1.553 















6.6 2.3 0.4 
Average B-factor 
      
Protein  86.5  99.5 73.6 90.6 
FAD  78.1  98.2 56.8 98.1 
NADP+  -  85.0 67.6 75.1 
Other ligands  -  102.3 57.0 126.6 
Solvent  54.0  48.9 56.5 62.4 
Statistics for the highest-resolution shell are shown in parentheses. Data derived from Aimless and 1173 
Staraniso used for AncFMO2 are described. 1174 
 1175 




Supplementary Table 2: Conversions by AncFMO2 and AncFMO3-6 variants.  1178 












>99 43 >99 >99 






Supplementary Table 3: Melting Temperatures of each AncFMO 1185 





















Supplementary Table 4: Ambiguously reconstructed sites in AncFMOs 1189 
AncFMO2 
Site ML State PP Alt State PP 
158 Q 0.64 E 0.33 
347 N 0.58 D 0.37 
AncFMO3-6 
4 K 0.59 R 0.31 
139 V 0.77 I 0.21 
158 E 0.77 D 0.20 
209 K 0.78 Q 0.20 
246 S 0.45 T 0.40 
276 G 0.67 S 0.20 
324 C 0.59 Y 0.40 
378 T 0.63 A 0.31 
509 S 0.40 Q 0.36 
510 L 0.75 P 0.22 
514 L 0.63 I 0.28 
517 I 0.54 L 0.28 
519 L 0.55 F 0.45 
520 F 0.60 C 0.37 
AncFMO5 
17 T 0.72 A 0.24 
35 T 0.62 S 0.21 
241 T 0.51 K 0.43 
253 S 0.56 I 0.39 
255 T 0.48 H 0.44 
410 S 0.66 T 0.20 
422 D 0.75 K 0.30 
439 I 0.76 L 0.21 
462 K 0.47 E 0.40 
504 I 0.60 V 0.49 
510 M 0.72 S 0.24 
 1190 
Ambiguously reconstructed sites defined by the Alt state highest posterior probability (PP)>0.2 are 1191 













Suplementary Data 1: FMOs sequences. Separate spreadsheet. 1203 
 1204 




























































For the three characterized ancestral proteins, sequences of the ML (maximum likelihood) ancestors 1242 
are shown. Graphs display the posterior probabilities of each reconstructed site for AncFMO2, 1243 
AncFMO3-6 and AncFMO5. 1244 
 1245 
 1246 
